AU2007262794B2 - Crystalline duloxetine hydrochloride - Google Patents

Crystalline duloxetine hydrochloride Download PDF

Info

Publication number
AU2007262794B2
AU2007262794B2 AU2007262794A AU2007262794A AU2007262794B2 AU 2007262794 B2 AU2007262794 B2 AU 2007262794B2 AU 2007262794 A AU2007262794 A AU 2007262794A AU 2007262794 A AU2007262794 A AU 2007262794A AU 2007262794 B2 AU2007262794 B2 AU 2007262794B2
Authority
AU
Australia
Prior art keywords
organic solvent
duloxetine
solution
duloxetine hydrochloride
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007262794A
Other languages
English (en)
Other versions
AU2007262794A1 (en
Inventor
Chun Rong Jia
Wei Ping Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Shenghuaxi Pharmaceutical Co Ltd
Arrow International Ltd
Original Assignee
Chongqing Shenghuaxi Pharmaceutical Co Ltd
Arrow International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Shenghuaxi Pharmaceutical Co Ltd, Arrow International Ltd filed Critical Chongqing Shenghuaxi Pharmaceutical Co Ltd
Publication of AU2007262794A1 publication Critical patent/AU2007262794A1/en
Application granted granted Critical
Publication of AU2007262794B2 publication Critical patent/AU2007262794B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AU2007262794A 2006-06-23 2007-06-21 Crystalline duloxetine hydrochloride Ceased AU2007262794B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612508.2 2006-06-23
GBGB0612508.2A GB0612508D0 (en) 2006-06-23 2006-06-23 Crystalline duloxetine hydrochloride
PCT/GB2007/002317 WO2007148096A1 (en) 2006-06-23 2007-06-21 Crystalline duloxetine hydrochloride

Publications (2)

Publication Number Publication Date
AU2007262794A1 AU2007262794A1 (en) 2007-12-27
AU2007262794B2 true AU2007262794B2 (en) 2012-04-12

Family

ID=36803803

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007262794A Ceased AU2007262794B2 (en) 2006-06-23 2007-06-21 Crystalline duloxetine hydrochloride

Country Status (10)

Country Link
US (1) US7795454B2 (enExample)
EP (1) EP2035403A1 (enExample)
JP (1) JP5247687B2 (enExample)
CN (1) CN101595099B (enExample)
AU (1) AU2007262794B2 (enExample)
BR (1) BRPI0712454A2 (enExample)
CA (1) CA2655962A1 (enExample)
GB (1) GB0612508D0 (enExample)
NZ (1) NZ572918A (enExample)
WO (1) WO2007148096A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612508D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
EP2107057A1 (en) * 2008-04-04 2009-10-07 Ranbaxy Laboratories Limited Process for the preparation of pure duloxetine hydrochloride
CZ304602B6 (cs) * 2009-09-02 2014-07-30 Zentiva, K. S. Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
JP6178817B2 (ja) * 2015-04-27 2017-08-09 株式会社豊田中央研究所 光輝性塗料組成物、光輝性樹脂膜、及び、積層塗膜
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
US12428668B2 (en) 2019-01-03 2025-09-30 Dna Script One pot synthesis of sets of oligonucleotides
CN113603673B (zh) * 2020-11-16 2024-08-06 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650965B1 (en) * 1993-10-12 2001-02-07 Eli Lilly And Company Asymmetric synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine an intermediate in the preparation of duloxetine
WO2005108386A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Crystalline forms of duloxetine free base
WO2006081515A2 (en) * 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US20050197503A1 (en) 2004-03-05 2005-09-08 Boehringer Ingelheim International Gmbh Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines
WO2006027798A2 (en) 2004-08-05 2006-03-16 Sun Pharmaceutical Industries Limited A process for preparation of an antidepressant compound
CZ297560B6 (cs) 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
EP1812428A2 (en) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
WO2006058121A1 (en) 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
EP1858874A1 (en) 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. (s)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
GB0612508D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650965B1 (en) * 1993-10-12 2001-02-07 Eli Lilly And Company Asymmetric synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine an intermediate in the preparation of duloxetine
WO2005108386A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Crystalline forms of duloxetine free base
WO2006081515A2 (en) * 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthon BV, Research Disclosure, 2005, Vol. DN498011, pages 1129-1131. *

Also Published As

Publication number Publication date
JP5247687B2 (ja) 2013-07-24
NZ572918A (en) 2011-12-22
JP2009541290A (ja) 2009-11-26
US7795454B2 (en) 2010-09-14
BRPI0712454A2 (pt) 2012-10-02
CN101595099A (zh) 2009-12-02
EP2035403A1 (en) 2009-03-18
US20080021090A1 (en) 2008-01-24
CA2655962A1 (en) 2007-12-27
GB0612508D0 (en) 2006-08-02
AU2007262794A1 (en) 2007-12-27
WO2007148096A1 (en) 2007-12-27
CN101595099B (zh) 2013-03-06

Similar Documents

Publication Publication Date Title
US7795454B2 (en) Crystalline duloxetine hydrochloride
AU2007262801B2 (en) Crystalline duloxetine hydrochloride
HK125993A (en) Piperidine derivative, its preparation, and its use as medicament
US7795455B2 (en) Crystalline duloxetine hydrochloride
UA66359C2 (uk) Спосіб одержання рацемічних або оптично активних сполук
WO2017097275A1 (en) Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
EP1971592A2 (en) Improved synthesis and preparations of duloxetine salts
CN112047888A (zh) 一种合成恩杂鲁胺的方法
WO2011091513A1 (en) Polymorphic forms of lubiprostone
CN118324648A (zh) (r)-特布他林苯磺酸盐a晶型和b晶型及其制备方法
JP2025533955A (ja) （２ｓ，５ｒ）－５－（２－クロロフェニル）－１－（２’－メトキシ－［１，１’－ビフェニル］－４－カルボニル）ピロリジン－２－カルボン酸の多形およびその調製プロセス
WO2006090265A2 (en) Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
CA2989364C (en) Process for the preparation of enclomiphene citrate having needle shaped crystal habit.
WO2009118758A2 (en) Novel crystalline forms of desvenlafaxine succinate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired